Injuries

TIDI Products announces the addition of the AquaGuard line of moisture barrier products to its portfolio

Retrieved on: 
Thursday, July 29, 2021
Health, Acute pain, First aid, Injuries, Wound, Surgery, Barrier isolator, Patient safety

NEENAH, Wis., July 29, 2021 /PRNewswire/ -- TIDI Products, LLC, a leading provider of medical technology solutions including Sterile-Z, C-Armor, TIDIShield, and Posey, today announced the addition of the AquaGuard line of moisture barrier products to its portfolio of patient safety products.

Key Points: 
  • NEENAH, Wis., July 29, 2021 /PRNewswire/ -- TIDI Products, LLC, a leading provider of medical technology solutions including Sterile-Z, C-Armor, TIDIShield, and Posey, today announced the addition of the AquaGuard line of moisture barrier products to its portfolio of patient safety products.
  • AquaGuard's specialized products provide patients with crucial moisture protection for wound, surgical, and vascular access sites throughout the body when showering.
  • The addition of AquaGuard to the TIDI portfolio aligns with TIDI's purpose, 'Support Caregivers.
  • About TIDI Products, LLC TIDI Products has a history of providing forward-looking solutions to healthcare professionalssolutions that help reduce the risk of contamination and deliver the highest-quality patient care.

KitoTech Medical Announces Jeff Willis Has Joined as Its Chief Commercial Officer

Retrieved on: 
Monday, July 26, 2021
First aid, Acute pain, Injuries, Wound, Clinical medicine, Medicine, Health

SEATTLE, July 26, 2021 /PRNewswire-PRWeb/ --KitoTech Medical, manufacturer of the microMend Wound Closure Product, announces today that Jeff Willis, an experienced executive in the wound closure space, has joined KitoTech as its Chief Commercial Officer.

Key Points: 
  • SEATTLE, July 26, 2021 /PRNewswire-PRWeb/ --KitoTech Medical, manufacturer of the microMend Wound Closure Product, announces today that Jeff Willis, an experienced executive in the wound closure space, has joined KitoTech as its Chief Commercial Officer.
  • He brings over 20 years of commercial experience in the medical device industry.
  • From 2005 to 2021, Jeff was at Advanced Medical Solutions Group plc (AMS), an advanced wound closure and wound care company with a $850 million market cap.
  • Jeff has a unique background with experience in both of our markets - medical and consumer.

Swift Medical Raises $35 Million Series B to Transform Wound Care Delivery with AI

Retrieved on: 
Thursday, July 15, 2021
Technology, Mobile, Wireless, Nursing, Hospitals, Software, Other Health, Managed care, Health, Data management, Clinical medicine, Medicine, First aid, Injuries, Medical emergencies, Acute pain, Wound, Health sciences

Swift Medical, the global leader in digital wound care, announced today a Series B funding round of $35 million USD.

Key Points: 
  • Swift Medical, the global leader in digital wound care, announced today a Series B funding round of $35 million USD.
  • This latest round of funding will help Swift Medical expand their leading market position and scale their digital wound management platform across the care continuum in North America.
  • With this investment, Swift Medical will be able to advance and accelerate its mission to transform the future of wound care: to prevent wounds before they even happen and improve quality of care for every patient with a wound.
  • Swift Medical is rapidly growing their team to take on the wound care epidemic.

United States Spinal Cord Injury Market and Competitive Landscape Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 14, 2021
Health, Pharmaceutical, Branches of biology, Neurotrauma, Nervous system, Neuroscience, Medical emergencies, Spinal cord, Injuries, Spinal cord injury, Spinal traction

The "US Spinal Cord Injury Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Spinal Cord Injury Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Spinal Cord Injury Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Spinal Cord Injury pipeline products, Spinal Cord Injury epidemiology, Spinal Cord Injury market valuations and forecast, Spinal Cord Injury drugs sales and competitive landscape in the US.
  • Spinal Cord Injury pipeline: Find out the products in clinical trials for the treatment of Spinal Cord Injury by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Spinal Cord Injury drugs: Identify key products marketed and prescribed for Spinal Cord Injury in the US, including trade name, molecule name, and company
    Spinal Cord Injury drugs sales: Find out the sales revenues of Spinal Cord Injury drugs in the US
    Spinal Cord Injury market valuations: Find out the market size for Spinal Cord Injury drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Spinal Cord Injury drugs market share: Find out the market shares for key Spinal Cord Injury drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Spinal Cord Injury products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005473/en/

New Study Demonstrates Significantly Increased Healing Rates with NATROX® Oxygen Wound Therapy

Retrieved on: 
Monday, July 12, 2021
Medicine, Clinical medicine, Branches of biology, Injuries, Acute pain, First aid, Wound, Healing, Chronic wound, Wound bed preparation

Patients completing the therapy experienced 71% greater healing rates and 73% greater reduction in wound size using NATROX.

Key Points: 
  • Patients completing the therapy experienced 71% greater healing rates and 73% greater reduction in wound size using NATROX.
  • NATROX Oxygen Wound Therapy is a class II medical device that uses the natural healing properties of oxygen.
  • Clinicians took photos of the wound, then the AI program automatically identified wound size and tracked healing rates.
  • The study indicates NATROX Oxygen Wound Therapy is poised to become the new standard in wound care and gives hope to patients suffering long-standing wounds.

New Study Demonstrates Significantly Increased Healing Rates with NATROX® Oxygen Wound Therapy

Retrieved on: 
Monday, July 12, 2021
Medicine, Clinical medicine, Branches of biology, Injuries, Acute pain, First aid, Wound, Healing, Chronic wound, Wound bed preparation

Patients completing the therapy experienced 71% greater healing rates and 73% greater reduction in wound size using NATROX.

Key Points: 
  • Patients completing the therapy experienced 71% greater healing rates and 73% greater reduction in wound size using NATROX.
  • NATROX Oxygen Wound Therapy is a class II medical device that uses the natural healing properties of oxygen.
  • Clinicians took photos of the wound, then the AI program automatically identified wound size and tracked healing rates.
  • The study indicates NATROX Oxygen Wound Therapy is poised to become the new standard in wound care and gives hope to patients suffering long-standing wounds.

MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal

Retrieved on: 
Friday, July 9, 2021
Medicine, Branches of biology, Clinical medicine, Physiology, Injuries, Debridement, Wound healing, Tissue engineering, Healing, Wound

The EscharEx arm achieved a significantly higher incidence of complete debridement compared to the gel vehicle arm, thus meeting the primary endpoint of this study.

Key Points: 
  • The EscharEx arm achieved a significantly higher incidence of complete debridement compared to the gel vehicle arm, thus meeting the primary endpoint of this study.
  • The EscharEx and gel vehicle arms achieved similar reductions in wound area, non-viable tissue area, and wound healing scores during the debridement period.
  • We are very excited to have our phase 2 data published in this respected journal.
  • MediWound is a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration.

InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021

Retrieved on: 
Tuesday, July 6, 2021
Research, Science, Corporate finance, Injuries, Neurotrauma, Spinal cord, Spinal cord injury, Common stock, Proxy, Branches of biology, Economy, Articles

Stockholders holding common stock at the close of business on Monday, May 17th, 2021 are entitled to vote at the meeting, even if they have subsequently sold their shares.

Key Points: 
  • Stockholders holding common stock at the close of business on Monday, May 17th, 2021 are entitled to vote at the meeting, even if they have subsequently sold their shares.
  • Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action.
  • InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology Company with a focus on treatment of spinal cord injuries.
  • Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties.

Insights on the Negative Pressure Wound Therapy Global Market to 2026 - Featuring Alkermes, Abbvie and AstraZeneca Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021
Health, General Health, Medicine, Clinical medicine, Health, Necrosis, Acute pain, First aid, Injuries, Wound, Pressure ulcer, COVID-19 pandemic, Negative-pressure wound therapy, Physical therapy

This situation put tremendous pressure on hospitals and other healthcare centers to provide services to COVID-19 patients.?

Key Points: 
  • This situation put tremendous pressure on hospitals and other healthcare centers to provide services to COVID-19 patients.?
  • As per the article published in The Wounds Clinic, 2020, the COVID-19 pandemic has changed the perspectives on the way wound clinics have been operating.
  • Therefore, owing to the aforementioned factors, North America is expected to have a significant share of the market studied.
  • Hence the rising aging population will increase the demand for negative pressure wound therapy.

IMAC Holdings Launches Acute Care Services for Musculoskeletal Injuries

Retrieved on: 
Thursday, July 1, 2021
Health, Medicine, Medical specialties, Injuries, Acute pain, Traumatology, Musculoskeletal injury, Acute, Physical medicine and rehabilitation, Sports injury, Telehealth

Acute Musculoskeletal Injuries include Motor Vehicle Accidents, Sports Injuries, and Work-Related Injuries.

Key Points: 
  • Acute Musculoskeletal Injuries include Motor Vehicle Accidents, Sports Injuries, and Work-Related Injuries.
  • Coinciding with the launch of this service, IMAC will provide physicians, lawyers, and referral sources a toll-free hotline for around-the-clock access to schedule patients with acute sports, accident, and work-related injuries.
  • IMAC currently delivers work-related injury rehabilitation services for the United States Department of Labor.
  • Patients in need of acute injury medical services may also contact the nearest IMAC facility to schedule an appointment for an onsite or telehealth evaluation.